BRPI0509459A - sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados - Google Patents

sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados

Info

Publication number
BRPI0509459A
BRPI0509459A BRPI0509459-3A BRPI0509459A BRPI0509459A BR PI0509459 A BRPI0509459 A BR PI0509459A BR PI0509459 A BRPI0509459 A BR PI0509459A BR PI0509459 A BRPI0509459 A BR PI0509459A
Authority
BR
Brazil
Prior art keywords
retinoid
manufacturing methods
related manufacturing
drug delivery
sustained release
Prior art date
Application number
BRPI0509459-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Patrick M Hughes
Orest Olejnik
Glenn T Huang
Joan-En Chang-Lin
Thierry Nivaggioli
Michele Boix
Christian Sarrazin
Jane Guo Shiah
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0509459A publication Critical patent/BRPI0509459A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
BRPI0509459-3A 2004-04-30 2005-04-29 sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados BRPI0509459A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56733904P 2004-04-30 2004-04-30
US62992804P 2004-11-22 2004-11-22
PCT/US2005/015018 WO2005107707A1 (en) 2004-04-30 2005-04-29 Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US11/119,024 US20050271705A1 (en) 2004-04-30 2005-04-29 Retinoid-containing sustained release intraocular drug delivery system and related methods

Publications (1)

Publication Number Publication Date
BRPI0509459A true BRPI0509459A (pt) 2007-09-04

Family

ID=34972221

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509459-3A BRPI0509459A (pt) 2004-04-30 2005-04-29 sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados

Country Status (9)

Country Link
US (3) US20050271705A1 (US20050271705A1-20051208-C00006.png)
EP (1) EP1765284A1 (US20050271705A1-20051208-C00006.png)
JP (1) JP2007535563A (US20050271705A1-20051208-C00006.png)
AR (1) AR056254A1 (US20050271705A1-20051208-C00006.png)
AU (1) AU2005240078A1 (US20050271705A1-20051208-C00006.png)
BR (1) BRPI0509459A (US20050271705A1-20051208-C00006.png)
CA (1) CA2565285A1 (US20050271705A1-20051208-C00006.png)
TW (1) TW200538163A (US20050271705A1-20051208-C00006.png)
WO (1) WO2005107707A1 (US20050271705A1-20051208-C00006.png)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
JP2007529434A (ja) 2004-03-17 2007-10-25 ラース マイケル ラーセン， 視覚サイクルの阻害による網膜症の予防
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7998717B2 (en) * 2005-12-02 2011-08-16 Pacific Biosciences Of California, Inc. Mitigation of photodamage in analytical reactions
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8492334B2 (en) 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CN102026599A (zh) 2008-05-12 2011-04-20 犹他大学研究基金会 眼内药物递送装置及相关方法
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
WO2009143288A1 (en) * 2008-05-20 2009-11-26 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
JP5890182B2 (ja) * 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US8834847B2 (en) 2010-08-12 2014-09-16 Pacific Biosciences Of California, Inc. Photodamage mitigation compounds and systems
EP2613776B1 (en) * 2010-09-01 2020-07-29 Thomas Jefferson University Composition and method for muscle repair and regeneration
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
RU2013157087A (ru) * 2011-06-03 2015-07-20 Аллерган, Инк. Целевая доставка ретиноидных соединений к сальным железам
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2013082149A1 (en) * 2011-11-28 2013-06-06 Case Western Reserve University Polysaccharide therapeutic conjugates
EP2918290B1 (en) * 2012-11-08 2020-09-02 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
EP2925314B1 (en) 2012-11-28 2020-04-01 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
US10123988B2 (en) 2013-03-15 2018-11-13 Allergan, Inc. Compositions including encapsulated isotretinoin and methods for use thereof
EP3446690A1 (en) 2013-05-22 2019-02-27 Yamaguchi University Inhibitor for retinochoroidal disorders
EP3099290A1 (en) 2014-01-28 2016-12-07 Allergan, Inc. Topical retinoid formulations and methods of use
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
WO2015184453A1 (en) 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
EP4249490A3 (en) 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
KR20190100187A (ko) 2016-11-16 2019-08-28 클레멘티아 파마슈티컬즈, 인크. 다중 골연골종(mo)을 치료하는 방법
CN111358766A (zh) * 2020-04-13 2020-07-03 青岛大学 一种包载他扎罗汀的plga纳米粒及其制备方法、用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
WO1999007418A2 (en) * 1997-08-11 1999-02-18 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
CA2432904C (en) * 2000-12-21 2007-09-11 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophobic active agents
EP1536819A4 (en) * 2002-03-29 2007-10-17 Maxim Pharm Inc USING THE PRODUCTION OF REACTIVE OXYGEN METABOLITES (ROM) AND RELEASE INHIBITORS TO TREAT AND PREVENT INTRAOCULAR DAMAGE
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing

Also Published As

Publication number Publication date
US20050271705A1 (en) 2005-12-08
EP1765284A1 (en) 2007-03-28
CA2565285A1 (en) 2005-11-17
TW200538163A (en) 2005-12-01
US20090163550A1 (en) 2009-06-25
JP2007535563A (ja) 2007-12-06
AR056254A1 (es) 2007-10-03
US20110076318A1 (en) 2011-03-31
AU2005240078A1 (en) 2005-11-17
WO2005107707A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
BRPI0509459A (pt) sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados
BRPI0510472A (pt) implantes intra-oculares de liberação prolongada antiexcitotóxicos e métodos relacionados
BRPI0510471A (pt) derivado de estradiol ou um derivado de estratopona contendo implante intra-ocular de liberação constante bem como métodos relacionados de fabricação
BRPI0510485A (pt) implantes inibidores de tirosina cinase intravìtreos biodegradáveis
Lee et al. Biodegradable implants for sustained drug release in the eye
BRPI0509461A (pt) implantes intravìtreos compreendendo microesferas que encapsulam um inibidor de tirosina cinase e um polìmero biodegradável
MX2010012022A (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular.
BRPI1007318A2 (pt) distribuição com liberação sustentada de um ou mais agentes.
BRPI0513243B8 (pt) composições oftálmicas e respectivos usos
BR112012026535A2 (pt) redução de pressão intraocular com implantes de bimatoprost intracameral
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
JP2010507686A5 (US20050271705A1-20051208-C00006.png)
SG170816A1 (en) Drug delivery methods, structures, and compositions for nasolacrimal system
HUP0001818A2 (hu) A szem első kamrájában alkalmazható szabályzott felszabadulású gyógyszerhatóanyagok
JP2007535539A5 (US20050271705A1-20051208-C00006.png)
BRPI0412496A (pt) fornecimento de um fármaco ativo para a parte posterior do olho através do fornecimento subconjuntival ou periocular de um pró-fármaco
BRPI0506983A (pt) composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
TW200605853A (en) Steroid-containing sustained release intraocular implants and related methods
BRPI0607606A2 (pt) formulações lìquidas para tratamento de doenças ou condições
BR0302584A (pt) Combinação de brimonidina e timolol para uso oftálmico tópico
AR064078A1 (es) Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion
EP2427174A4 (en) HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE
RU2011106329A (ru) Глазное устройство, обладающее способностью доставки терапевтического средства и способ получения такового
Tao et al. Role of corneal epithelium in riboflavin/ultraviolet-A mediated corneal cross-linking treatment in rabbit eyes
BR112013018739A2 (pt) sistema de distribuição de medicamento ocular

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.